HRP20180906T1 - Postupak predviđanja odgovora tumorske bolesti na terapijske mjere - Google Patents
Postupak predviđanja odgovora tumorske bolesti na terapijske mjere Download PDFInfo
- Publication number
- HRP20180906T1 HRP20180906T1 HRP20180906TT HRP20180906T HRP20180906T1 HR P20180906 T1 HRP20180906 T1 HR P20180906T1 HR P20180906T T HRP20180906T T HR P20180906TT HR P20180906 T HRP20180906 T HR P20180906T HR P20180906 T1 HRP20180906 T1 HR P20180906T1
- Authority
- HR
- Croatia
- Prior art keywords
- tumor cells
- cells
- epithelial
- epithelial tumor
- therapeutic measures
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 12
- 230000001225 therapeutic effect Effects 0.000 title claims 7
- 206010028980 Neoplasm Diseases 0.000 title claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 210000004881 tumor cell Anatomy 0.000 claims 20
- 210000001124 body fluid Anatomy 0.000 claims 5
- 239000010839 body fluid Substances 0.000 claims 5
- 210000004027 cell Anatomy 0.000 claims 4
- 239000001963 growth medium Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 2
- 239000008280 blood Substances 0.000 claims 2
- 238000004113 cell culture Methods 0.000 claims 2
- 239000006143 cell culture medium Substances 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 239000000523 sample Substances 0.000 claims 2
- 206010003445 Ascites Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010073306 Exposure to radiation Diseases 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 230000001085 cytostatic effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000003743 erythrocyte Anatomy 0.000 claims 1
- 210000000416 exudates and transudate Anatomy 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 230000005484 gravity Effects 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Physiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Electrotherapy Devices (AREA)
Claims (11)
1. Postupak predviđanja odgovora tumorske bolesti kod pacijenta, uzrokovane čvrstim epitelnim tumorom, na terapijske mjere, naznačen time što se epitelne tumorske stanice iz pacijentove tjelesne tekućine u svakom slučaju prebaci u medij za uzgoj stanica u kulturi, gdje tumorske stanice iz uzorka medija za uzgoj stanica u kulturi koji sadrži tumorske stanice se podvrgne terapijskim mjerama, dok tumorske stanice iz kontrolnog uzorka medija za uzgoj stanica u kulturi koji sadrži tumorske stanice ostaju netretirane, gdje se zatim odredi udio umirućih i mrtvih epitelnih tumorskih stanica u ukupnom broju epitelnih tumorskih stanica za uzorak odnosno kontrolni uzorak, te upotrijebi za određivanje stope umiranja epitelnih tumorskih stanica uzrokovanog terapijskim mjerama kao mjeru odgovora, gdje medij za uzgoj stanica u kulturi ne sadrži nikakav dodani čimbenik rasta ili dodani serum.
2. Postupak u skladu s patentnim zahtjevom 1, naznačen time što prođe vremenski interval od 1 sata do 3 dana, osobito od 2 sata do 1 dana, između terapijskih mjera i određivanja udjela umirućih i mrtvih epitelnih tumorskih stanica u ukupnom broju epitelnih tumorskih stanica.
3. Postupak u skladu s patentnim zahtjevom 2, naznačen time što se u tom vremenskom intervalu tumorske stanice drži u uvjetima uzgoja stanica u kulturi koji omogućuju preživljenje tumorskih stanica u mediju za uzgoj stanica u kulturi bez terapijskih mjera.
4. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je tjelesna tekućina krv, ascitesna tekućina, limfa, pleuralni eksudat, likvor ili mokraća.
5. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su epitelne tumorske stanice cirkulirajuće epitelne tumorske stanice (CETCs).
6. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se tumorske stanice, prije nego ih se prebaci u medij za kulturu, obogaćuje zahvaljujući činjenici da je njihova specifična težina veća od one tjelesne tekućine koja ih okružuje, osobito tako što im se dopusti da se slegnu ili ih se centrifugira.
7. Postupak u skladu s patentnim zahtjevom 6, naznačen time što je tjelesna tekućina krv, a tamo prisutne eritrocite se lizira prije obogaćivanja tumorskih stanica.
8. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što epitelne tumorske stanice se dovodi u kontakt s tvari koja specifično obilježava tumorske stanice, osobito s protutijelom specifičnim za epitelne stanice, kako bi se navedene epitelne tumorske stanice razlikovalo od drugih stanica prisutnih u tjelesnoj tekućini.
9. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što se epitelnim tumorskim stanicama dodaje prvi indikator koji specifično ukazuje na umiruće i/ili mrtve stanice, osobito propidijev jodid, ili drugi indikator koji specifično ukazuje na žive stanice.
10. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što terapijske mjere se sastoje u izlaganju zračenju ili toplini ili dovođenju u kontakt s citostatikom, osobito 5-fluoruracilom, ili s bilo kojim drugim terapijskim sredstvom usmjerenim protiv tumora.
11. Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što je tumor karcinom dojke ili karcinom bronha.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE200910047146 DE102009047146B4 (de) | 2009-11-25 | 2009-11-25 | Verfahren zum Vorhersagen des Ansprechens einer Tumorerkrankung auf eine therapeutische Maßnahme |
| EP10787078.4A EP2504698B1 (de) | 2009-11-25 | 2010-11-25 | Verfahren zum vorhersagen des ansprechens einer tumorerkrankung auf eine therapeutische massnahme |
| PCT/EP2010/068235 WO2011064308A1 (de) | 2009-11-25 | 2010-11-25 | Verfahren zum vorhersagen des ansprechens einer tumorerkrankung auf eine therapeutische massnahme |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180906T1 true HRP20180906T1 (hr) | 2018-08-24 |
Family
ID=43413696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180906TT HRP20180906T1 (hr) | 2009-11-25 | 2018-06-11 | Postupak predviđanja odgovora tumorske bolesti na terapijske mjere |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP2504698B1 (hr) |
| JP (1) | JP5926187B2 (hr) |
| CA (1) | CA2781727C (hr) |
| DE (1) | DE102009047146B4 (hr) |
| DK (1) | DK2504698T3 (hr) |
| ES (1) | ES2673514T3 (hr) |
| HR (1) | HRP20180906T1 (hr) |
| HU (1) | HUE037770T2 (hr) |
| PL (1) | PL2504698T3 (hr) |
| PT (1) | PT2504698T (hr) |
| SI (1) | SI2504698T1 (hr) |
| TR (1) | TR201808349T4 (hr) |
| WO (1) | WO2011064308A1 (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102012213838A1 (de) * | 2012-08-03 | 2014-02-06 | Katharina Pachmann | Verfahren zur Kultivierung einer Subpopulation zirkulierender epithelialer Tumorzellen aus einer Körperflüssigkeit |
| DE102013010528B3 (de) * | 2013-06-25 | 2014-02-20 | FLACOD GmbH | Verfahren zur Erstellung einer Datenbank für die Vorabschätzung der Wirksamkeit von Wirkstoffen in der Tumortherapie |
| GB201507894D0 (en) | 2015-05-08 | 2015-06-24 | Imagen Biotech Ltd | Personalised media |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19833738A1 (de) | 1998-07-27 | 2000-02-03 | Michael Giesing | Verfahren zur Isolierung von Krebszellen aus zellhaltigen Körperflüssigkeiten sowie Sets zur Durchführung dieses Verfahrens |
| AU2002306561A2 (en) | 2001-02-16 | 2003-09-02 | Immunivest Corporation | Methods and reagents for the rapid and efficient isolation of circulating cancer cells |
| KR20080066663A (ko) | 2005-09-21 | 2008-07-16 | 씨씨씨 디아그노스틱스 엘엘씨 | 맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법 |
-
2009
- 2009-11-25 DE DE200910047146 patent/DE102009047146B4/de active Active
-
2010
- 2010-11-25 HU HUE10787078A patent/HUE037770T2/hu unknown
- 2010-11-25 CA CA2781727A patent/CA2781727C/en active Active
- 2010-11-25 EP EP10787078.4A patent/EP2504698B1/de active Active
- 2010-11-25 PL PL10787078T patent/PL2504698T3/pl unknown
- 2010-11-25 WO PCT/EP2010/068235 patent/WO2011064308A1/de active Application Filing
- 2010-11-25 DK DK10787078.4T patent/DK2504698T3/en active
- 2010-11-25 TR TR2018/08349T patent/TR201808349T4/tr unknown
- 2010-11-25 JP JP2012540434A patent/JP5926187B2/ja active Active
- 2010-11-25 SI SI201031705T patent/SI2504698T1/sl unknown
- 2010-11-25 PT PT107870784T patent/PT2504698T/pt unknown
- 2010-11-25 ES ES10787078.4T patent/ES2673514T3/es active Active
-
2018
- 2018-06-11 HR HRP20180906TT patent/HRP20180906T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2504698A1 (de) | 2012-10-03 |
| CA2781727A1 (en) | 2011-06-03 |
| SI2504698T1 (sl) | 2018-09-28 |
| HUE037770T2 (hu) | 2018-09-28 |
| EP2504698B1 (de) | 2018-03-14 |
| PL2504698T3 (pl) | 2018-10-31 |
| DK2504698T3 (en) | 2018-06-18 |
| TR201808349T4 (tr) | 2018-07-23 |
| CA2781727C (en) | 2018-06-05 |
| PT2504698T (pt) | 2018-06-20 |
| DE102009047146B4 (de) | 2012-07-19 |
| JP2013511968A (ja) | 2013-04-11 |
| JP5926187B2 (ja) | 2016-05-25 |
| ES2673514T3 (es) | 2018-06-22 |
| DE102009047146A1 (de) | 2011-06-01 |
| WO2011064308A1 (de) | 2011-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m6A RNA methylation | |
| Carcereri de Prati et al. | Metastatic breast cancer cells enter into dormant state and express cancer stem cells phenotype under chronic hypoxia | |
| Liu et al. | Retracted: Effects of MicroRNA‐19b on the Proliferation, Apoptosis, and Migration of Wilms’ Tumor Cells Via the PTEN/PI3K/AKT Signaling Pathway | |
| HRP20180906T1 (hr) | Postupak predviđanja odgovora tumorske bolesti na terapijske mjere | |
| Cahu et al. | Senescence-associated secretory phenotype favors the emergence of cancer stem-like cells | |
| Xia et al. | Exosome‐mediated transfer of miR‐1260b promotes cell invasion through Wnt/β–catenin signaling pathway in lung adenocarcinoma | |
| Mas-Bargues et al. | Extracellular vesicles from healthy cells improves cell function and stemness in premature senescent stem cells by miR-302b and HIF-1α activation | |
| Wu et al. | Expressions and clinical significances of c-MET, p-MET and E2f-1 in human gastric carcinoma | |
| Kim et al. | A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients | |
| Tóth et al. | Circadian rhythm of methylated septin 9, cell-free DNA amount and tumor markers in colorectal cancer patients | |
| Song et al. | RETRACTED ARTICLE: Down-regulated lncRNA TP73-AS1 reduces radioresistance in hepatocellular carcinoma via the PTEN/Akt signaling pathway | |
| Dai et al. | MiR-17-5p and MKL-1 modulate stem cell characteristics of gastric cancer cells | |
| An et al. | Circulating microvesicles from pancreatic cancer accelerate the migration and proliferation of PANC-1 cells | |
| Shen et al. | Physical confinement during cancer cell migration triggers therapeutic resistance and cancer stem cell-like behavior | |
| Jaramillo-Rangel et al. | Nestin-expressing cells in the lung: the bad and the good parts | |
| Gao et al. | DT-13 inhibits breast cancer cell migration via non-muscle myosin II-A regulation in tumor microenvironment synchronized adaptations | |
| Contag et al. | Monitoring dynamic interactions between breast cancer cells and human bone tissue in a co-culture model | |
| Alhaddad et al. | Polyploid/Multinucleated giant and slow-cycling cancer cell enrichment in response to X-ray irradiation of human glioblastoma multiforme cells differing in radioresistance and TP53/PTEN status | |
| Ni et al. | Prospective study of the relevance of circulating tumor cell status and neoadjuvant chemotherapy effectiveness in early breast cancer | |
| CN102168085A (zh) | 抑制miR-130b基因表达的siRNA和表达载体及其在制备提高肝癌治疗效果的药物中的应用 | |
| Wu et al. | Alteration of galectin-1 during tumorigenesis of Opisthorchis viverrini infection-induced cholangiocarcinoma and its correlation with clinicopathology | |
| CN102558336B (zh) | Prr11基因及其编码的蛋白和应用 | |
| Purushothaman et al. | Differential effects of pancreatic cancer-derived extracellular vesicles driving a suppressive environment | |
| CN111893182A (zh) | 柠檬酸合成酶在制备诊断、评估前列腺癌的试剂盒中的应用 | |
| He et al. | Association of SOX11 gene expression with clinical features and prognosis of mantle cell lymphoma. |